MedWatch

Zuniga Health's 'Elevate' health plans fit the needs for Hispanic small businesses

Retrieved on: 
Thursday, March 28, 2024
MEC, MVP, Growth, MedWatch, Patient, Small business, Telehealth, Elevate, Insurance, Language, Multimedia, Dentist, UCLA, ACA, Hospital, Health insurance

MIAMI, March 28, 2024 /PRNewswire/ -- Zuniga Health LLC, an innovative health plan for small and medium-sized businesses recently launched Elevate, a new set of health plans that directly addresses the needs of Hispanic small businesses.

Key Points: 
  • MIAMI, March 28, 2024 /PRNewswire/ -- Zuniga Health LLC, an innovative health plan for small and medium-sized businesses recently launched Elevate, a new set of health plans that directly addresses the needs of Hispanic small businesses.
  • Zuniga Health is the only Hispanic-owned health plan in the US to address this issue.
  • Zuniga Health seeks to elevate the Hispanic business community through its mission of increasing the number of Hispanic employees obtaining affordable and accessible health benefits.
  • Zuniga Health's Elevate, a new set of unique health plans, are the solution to any small business struggling to offer health insurance, as they are designed to meet every employee's budget.

IHPlans Enhance Member Experience through Medwatch Concierge Member Advocacy

Retrieved on: 
Wednesday, February 7, 2024
Partnership, MedWatch, Partner (business rank), MVP, BOCA, IHP, MEC, URAC, Education, Concierge, Health, Maxima and minima, Nursing

BOCA RATON, Fla., Feb. 7, 2024 /PRNewswire/ -- IHPlans [IHP], a national alternative health insurance company, has enhanced its plan member experience and education through the introduction of Concierge Member Advocacy.

Key Points: 
  • BOCA RATON, Fla., Feb. 7, 2024 /PRNewswire/ -- IHPlans [IHP], a national alternative health insurance company, has enhanced its plan member experience and education through the introduction of Concierge Member Advocacy.
  • Medwatch is a population health management company with more than 35 years of experience.
  • "Our partnership with MedWatch helps members make the most informed decisions possible surrounding their health," said Mike Feeney, Managing Partner, of IHP.
  • IHP and MedWatch have joined forces to broaden member access to exceptional and customizable support and advocacy.

Olympus Issues Voluntary Field Action to Remind Users of Warnings for Bronchoscopes Used with High-Frequency Therapy Equipment

Retrieved on: 
Thursday, November 9, 2023
Safety, Food, Laser, ICU, Patient, Multimedia, Operations manual, FDA, Perforation, Olympus Corporation, MedWatch, Bleeding, Burns, Death, Bronchoscopic lung volume reduction, Letter, Hospital, Medical device

Olympus took action to notify users about these complaints and reinforce existing warnings for use of bronchoscopes with high-frequency therapy equipment.

Key Points: 
  • Olympus took action to notify users about these complaints and reinforce existing warnings for use of bronchoscopes with high-frequency therapy equipment.
  • Olympus bronchoscopes compatible for use with specified high-frequency therapy equipment can continue to be used following the instructions and warnings contained in the Olympus Operation Manual.
  • Olympus is reminding users to pay careful attention to warnings in the Operation Manual on high-frequency cauterization with Olympus bronchoscopes.
  • Users may continue to use the device according to the existing instructions and warnings contained in the Operation Manual.

Philips Respironics alerts customers worldwide of updated instructions and labeling of specific sleep therapy masks that contain magnetic headgear clips due to potential risk of serious injury

Retrieved on: 
Tuesday, September 6, 2022
Magnet, AICD, VP, Caregiver, Fisher's Lane Bridge, Respironics, Philips, Seizure, Head, CSF, Neck, DME, Hearing, Durable medical equipment, Patient, Mask, HF-2, FDA, Field line, Arrhythmia, MedWatch, Torso, Medical device, Medical imaging

Patients should consult their physician immediately to determine if another mask can be used for their therapy.

Key Points: 
  • Patients should consult their physician immediately to determine if another mask can be used for their therapy.
  • This includes household members, caregivers, and bed partners that may be in close vicinity to patients that use the masks.
  • More than 17 million masks containing magnetic clips have been distributed by Philips Respironics to date.
  • This voluntary medical device corrective action has been reported to the regulatory agencies in the countries where these masks are available.

Babyganics Issues Voluntary Recall of Select Lots of Babyganics® 20oz Chamomile Verbena Bubble Bath Bottles Due to Possible Bacterium Contamination

Retrieved on: 
Tuesday, April 19, 2022
Parent, Immunodeficiency, FDA, Skin, Risk, Seborrhoeic dermatitis, Method, MedWatch, Infection, Bottled water

RACINE, Wis., April 19, 2022 /PRNewswire/ -- Babyganics is voluntarily recalling two lots of 20-ounce bottles of babyganics® 20oz chamomile verbena bubble bath, due to the presence of the bacterium Pluralibacter gergoviae.

Key Points: 
  • RACINE, Wis., April 19, 2022 /PRNewswire/ -- Babyganics is voluntarily recalling two lots of 20-ounce bottles of babyganics 20oz chamomile verbena bubble bath, due to the presence of the bacterium Pluralibacter gergoviae.
  • During internal testing related to product shelf life across the Babyganics bubble bath line, it was discovered that two specific lot numbers of this product contained the bacterium.
  • While infants may be more susceptible than adults, Pluralibacter gergoviae does not usually cause healthy individuals to become sick.
  • The products were sold in the last two months only at select retailers in the U.S. Our testing confirmed that no other Babyganics products contained this bacterium.

Marpai's AI-Powered Health Predictions Gain Traction with URAC Accredited Care Management

Retrieved on: 
Thursday, January 13, 2022
COPD, Forward-looking statement, Technology, SEC, URAC, Growth, SMART, CEO, MedWatch, U.S. Securities and Exchange Commission, Deep learning, Disease management, Consultant, Aetna, TPA, Cardiovascular disease, Diabetes, Conditional sentence, Security (finance), Risk, Medical device, Health insurance, Cigna

Marpai Care Guides work with members to assist in creating the right care journey for the best possible health outcomes.

Key Points: 
  • Marpai Care Guides work with members to assist in creating the right care journey for the best possible health outcomes.
  • For chronic illness related health predictions, a Marpai Care Guide reaches out to work with identified members to assist them in creating the right care journey for the best health outcomes.
  • The Marpai Care Guides are licensed clinicians provided by MedWatch, a nationally acclaimed triple URAC accredited care management company.
  • "Marpai Cares brings accredited best-in-class clinicians and practices that can help to ensure the best care and disease management experience possible for our members," says Edmundo Gonzalez, CEO of Marpai.

Accumulus Synergy Announce the Appointment of Christopher Jeschke as Chief Technology Officer

Retrieved on: 
Thursday, October 21, 2021
Safety, Method, Engineering, Johns Hopkins, Compliance, Chemistry, Patient safety, University, Organization, Security, Software as a service, Patient, FDA, Ministry of Education (Malaysia), Data science, Center for Drug Evaluation and Research, Center, Intelligence, MedWatch, CEO, History of the University of Maryland, College Park, Privacy, R, Solution, Health, Acquisition, College Park, Chris, GLOBE, CTO, AI, Medical device, Management

BURLINGAME, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Accumulus Synergy, a non-profit corporation working to develop an information and data exchange platform aimed at transforming how drug innovators and health authorities worldwide interact, today announced the company has appointed Christopher Jeschke as its chief technology officer (CTO).

Key Points: 
  • BURLINGAME, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Accumulus Synergy, a non-profit corporation working to develop an information and data exchange platform aimed at transforming how drug innovators and health authorities worldwide interact, today announced the company has appointed Christopher Jeschke as its chief technology officer (CTO).
  • Chris joins Accumulus Synergy from Protenus, the nation's leading cybersecurity company focused on privacy, security, and compliance threats within our nations healthcare institutions, where he served as the CTO.
  • He is an experienced technical leader and an expert in engineering highly secure SaaS solutions for health and life science needs.
  • As Protenus grew, Chris was both the chief architect for the Protenus platform, and their executive responsible for all Engineering, R&D, Product and Security functions.

ASDSA Applauds FDA for Safety Communication on Needle-less Injector Devices

Retrieved on: 
Monday, October 11, 2021
MedWatch, Sodium hyaluronate, Department, Northwestern University, Food, Physician, JD, Safety, Education, FDA, MD, Society, HA, Regulation of tobacco by the U.S. Food and Drug Administration, Communication, Lip, Association, Knowledge, Partnership, Patient, Social media, Medical device, Pharmaceutical industry

ASDSA had earlier sounded the alarm on these devices and has resources available on these devices, including a downloadable flyer , and raised this issue with the FDA.

Key Points: 
  • ASDSA had earlier sounded the alarm on these devices and has resources available on these devices, including a downloadable flyer , and raised this issue with the FDA.
  • ASDSA members, board certified dermatologists, have found questionable social media videos in which children use these devices to self-inject and promote their use to peers.
  • ASDSA members should also report applicable events to MedWatch , the FDA Safety Information and Adverse Event Reporting program.
  • ASDSA's top priority is patient safety and the FDA's safety communication on these devices will help ensure consumers know the risks of self-injecting fillers.

FDA Approves Innovative Treatment for Pediatric Patients with Congenital Athymia

Retrieved on: 
Friday, October 8, 2021
Center for Biologics Evaluation and Research, MedWatch, Public health, Risk, Therapy, Office of Inspector General, U.S. Department of Health and Human Services, Life, Cytokine release syndrome, Food, Multimedia, Survival, Safety, Guidance, Research, Human services, FDA, Child, Birth defect, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Immune reconstitution inflammatory syndrome, Infection, Body surface area, Dietary supplement, Immune disorder, Rash, Vaccine, Health care, Smokeless tobacco, Animal, Cosmetics, Patient, Disease, Immunity, China Biologic Products, Center, SCID, Pharmaceutical industry, Generic drug

SILVER SPRING, Md., Oct. 8, 2021 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Rethymic for the treatment of pediatric patients with congenital athymia, a rare immune disorder.

Key Points: 
  • SILVER SPRING, Md., Oct. 8, 2021 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Rethymic for the treatment of pediatric patients with congenital athymia, a rare immune disorder.
  • Congenital athymia is a rare immune disorder in which a child is born without a thymus an organ that plays a critical role in helping the body learn to fight infections.
  • Rethymic improved survival of children with congenital athymia, and most children treated with this product survived at least two years.
  • A description of rare pediatric disease designation and voucher programs can be found in the Guidance for Industry: Rare Pediatric Disease Priority Review Vouchers .

FDA Alerts Health Care Providers to Stop New Implants of Certain Ventricular Assist Device System

Retrieved on: 
Thursday, June 3, 2021
Food and Drug Administration, Health, MedWatch, Clinical research, Medtronic, Medical device, Adverse event, FDA Adverse Event Reporting System

Medtronic is stopping the distribution and sale of the HVAD System and has issued an Urgent Medical Device Communication Notification Letter requesting physicians to stop new implants of the device.

Key Points: 
  • Medtronic is stopping the distribution and sale of the HVAD System and has issued an Urgent Medical Device Communication Notification Letter requesting physicians to stop new implants of the device.
  • "The FDA's alertis designed to quickly inform health care providers of this critical information so that patients with the current HVAD System continue to receive appropriate care and management.
  • The FDA will continue to monitor adverse events associated with the HVAD System and keep health care providers and the public informed as new or additional information becomes available.
  • The FDA encourages health care professionals and patients to report adverse events or safety problems with the Medtronic HVAD System to FDA's MedWatch Adverse Event Reporting program.